title: A non-replicating oncolytic vector as a novel therapeutic tool against cancer.
abstract: Cancers are still difficult targets despite recent advances in cancer therapy. Due to the heterogeneity of cancer, a single-treatment modality is insufficient for the complete elimination of cancer cells. Therapeutic strategies from various aspects are needed. Gene therapy has been expected to bring a breakthrough to cancer therapy, but it has not yet been successful. Gene therapy also should be combined with other treatments to enhance multiple therapeutic pathways. In this view, gene delivery vector itself should be equipped with intrinsic anti-cancer activities. HVJ (hemagglutinating virus of Japan; Sendai virus) envelope vector (HVJ-E) was developed to deliver therapeutic molecules. HVJ-E itself possessed anti-tumor activities such as the generation of anti-tumor immunities and the induction of cancer-selective apoptosis. In addition to the intrinsic anti-tumor activities, therapeutic molecules incorporated into HVJ-E enabled to achieve multi-modal therapeutic strategies in cancer treatment. Tumor-targeting HVJ-E was also developed. Thus, HVJ-E will be a novel promising tool for cancer treatment.
authors.affiliation: Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, Japan. kaneday@gts.med.osaka-u.ac.jp
authors.forename: Yasufumi
authors.initials: Y
authors.lastname: Kaneda
mesh_terms: D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D009369:Neoplasms / Q000628:therapy*; D050504:Oncolytic Viruses / Q000235:genetics*; D029082:Sendai virus / Q000235:genetics*; D013601:T-Lymphocytes / Q000276:immunology